WeTrials
Active, not recruiting

Immunologic Targeting of Native and Mutated ESR1 Receptor for Treatment of Hormone Receptor Expressing Metastatic Breast Cancer

What is this study?

This early-stage study tests a new combination treatment using a special immune-boosting vaccine and a hormone-blocking medication called elacestrant. Researchers want to see if this approach is safe and feasible for treating advanced breast cancer.

Who can participate?

You might be eligible if you have hormone-positive, HER2-negative breast cancer that has spread, and genetic testing shows a specific change called an ESR1 mutation. You must have also tried previous hormone therapies and a CDK 4/6 inhibitor drug.

What will happen?

Participants will receive the study treatments, which include the elacestrant medication and specialized vaccines, while doctors carefully monitor your health and safety. You will also have regular check-ins and medical tests to see how your body responds to the treatment.

Where and when?

This study currently takes place in Tampa, Florida, and is active but not currently looking for new participants.

Key Points
  • 1Tests a combination of an immune vaccine and a hormone-blocking drug.
  • 2Specifically for advanced breast cancer with a certain gene change.
  • 3Currently active in Tampa, Florida, but not recruiting new patients.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Breast Cancer Metastatic Breast CancerHER2-negative Breast Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.